Green and Red Brazilian Propolis: Antimicrobial Potential and Anti-Virulence against ATCC and Clinically Isolated Multidrug-Resistant Bacteria
- PMID: 34086414
- DOI: 10.1002/cbdv.202100307
Green and Red Brazilian Propolis: Antimicrobial Potential and Anti-Virulence against ATCC and Clinically Isolated Multidrug-Resistant Bacteria
Abstract
Brazilian green and red propolis stand out as commercial products for different medical applications. In this article, we report the antimicrobial activities of the hydroalcoholic extracts of green (EGP) and red (ERP) propolis, as well as guttiferone E plus xanthochymol (8) and oblongifolin B (9) from red propolis, against multidrug-resistant bacteria (MDRB). We undertook the minimal inhibitory (MIC) and bactericidal (MBC) concentrations, inhibition of biofilm formation (MICB50 ), catalase, coagulase, DNase, lipase, and hemolysin assays, along with molecular docking simulations. ERP was more effective by displaying MIC and MBC values <100 μg mL-1 . Compounds 8 and 9 displayed the lowest MIC values (0.98 to 31.25 μg mL-1 ) against all tested Gram-positive MDRB. They also inhibited the biofilm formation of S. aureus (ATCC 43300 and clinical isolate) and S. epidermidis (ATCC 14990 and clinical isolate), with MICB50 values between 1.56 and 6.25 μg mL-1 . The molecular docking results indicated that 8 and 9 might interact with the catalase's amino acids. Compounds 8 and 9 have great antimicrobial potential.
Keywords: antibacterial activity; green propolis; guttiferone E; oblongifolin; red propolis; xanthochymol.
© 2021 Wiley-VHCA AG, Zurich, Switzerland.
Similar articles
-
Bioassay guided purification of the antimicrobial fraction of a Brazilian propolis from Bahia state.BMC Complement Altern Med. 2009 Jul 30;9:25. doi: 10.1186/1472-6882-9-25. BMC Complement Altern Med. 2009. PMID: 19643008 Free PMC article.
-
Characterization of Brazilian green propolis as a photosensitizer for LED light-induced antimicrobial photodynamic therapy (aPDT) against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-intermediate Staphylococcus aureus (VISA).Photochem Photobiol Sci. 2023 Dec;22(12):2877-2890. doi: 10.1007/s43630-023-00495-1. Epub 2023 Nov 3. Photochem Photobiol Sci. 2023. PMID: 37923909
-
Anti-inflammatory and antimicrobial evaluation of neovestitol and vestitol isolated from Brazilian red propolis.J Agric Food Chem. 2013 May 15;61(19):4546-50. doi: 10.1021/jf305468f. Epub 2013 May 3. J Agric Food Chem. 2013. PMID: 23607483
-
Antibacterial Properties of Propolis.Molecules. 2019 May 29;24(11):2047. doi: 10.3390/molecules24112047. Molecules. 2019. PMID: 31146392 Free PMC article. Review.
-
A review on the anti-inflammatory activities of Brazilian green, brown and red propolis.J Food Biochem. 2022 Oct;46(10):e14350. doi: 10.1111/jfbc.14350. Epub 2022 Jul 26. J Food Biochem. 2022. PMID: 35880944 Review.
Cited by
-
Experimental Evidence for Therapeutic Potentials of Propolis.Nutrients. 2021 Jul 24;13(8):2528. doi: 10.3390/nu13082528. Nutrients. 2021. PMID: 34444688 Free PMC article. Review.
-
Potential in vitro anti-periodontopathogenic, anti-Chikungunya activities and in vivo toxicity of Brazilian red propolis.Sci Rep. 2022 Dec 7;12(1):21165. doi: 10.1038/s41598-022-24776-4. Sci Rep. 2022. PMID: 36477635 Free PMC article.
-
Development of a Benzophenone-Free Red Propolis Extract and Evaluation of Its Efficacy against Colon Carcinogenesis.Pharmaceuticals (Basel). 2024 Oct 8;17(10):1340. doi: 10.3390/ph17101340. Pharmaceuticals (Basel). 2024. PMID: 39458981 Free PMC article.
-
Anti-Biofilm Perspectives of Propolis against Staphylococcus epidermidis Infections.Biomolecules. 2024 Jun 29;14(7):779. doi: 10.3390/biom14070779. Biomolecules. 2024. PMID: 39062493 Free PMC article.
-
Antibacterial, antibiofilm, and antivirulence potential of the main diterpenes from Copaifera spp. oleoresins against multidrug-resistant bacteria.Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6975-6987. doi: 10.1007/s00210-024-03077-9. Epub 2024 Apr 15. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38619589
References
-
- B. Anne-Sophie, G. Benoit, ‘Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?’, Swiss Med. Wkly. 2017, 147.
-
- R. Barbieri, E. Coppo, A. Marchese, M. Daglia, E. Sobarzo-Sanchez, S. F. Nabavi, S. M. Nabavi, ‘Phytochemicals for human disease: An update on plant-derived compounds antibacterial activity’, Microbiol. Res. 2017, 196, 44-68.
-
- D. Koulenti, E. Xu, A. Song, I. Y. S. Mok, D. E. Karageorgopoulos, A. Armaganidis, S. Tsiodras, J. Lipman, ‘Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms’, Microorganisms 2020, 8, 191-230.
-
- I. S. D. Silva, L. M. D. C. Gaspar, A. M. O. Rocha, L. P. da Costa, D. B. Tada, E. Franceschi, F. F. Padilba, ‘Encapsulation of Red Propolis in Polymer Nanoparticles for the Destruction of Pathogenic Biofilms’, AAPS PharmSciTech 2020, 21.
-
- D. J. Newman, G. M. Cragg, ‘Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019’, J. Nat. Prod. 2020, 83, 770-803.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
